Corrigendum to “The Impact of Type 2 Diabetes Mellitus on Long-Term Prognosis in Patients of Different Ages with Myocardial Infarction”

IntroductionInhibitors of sodium-glucose linked transporter-2 (SGLT2i) are enhancing glucose excretion in the proximal renal tubules, and thus are increasingly used to lower blood glucose levels in patients with type 2 diabetes mellitus (T2DM). The glucose analog 2-deoxy-2-(18F) fluoro-D-glucose (FDG) can be used to quantify renal function in vivo, and due to an affinity for SGLT2 could also provide information about SGLT2 transporter function. Our objectives in this study were, therefore, to assess the impact of SGLT2i on renal function parameters in patients with T2DM and identify predictive parameters of long-term response to SGLT2i using dynamic FDG positron emission tomography (PET)/MRI.MethodsPET FDG renal function measures such as mean transit time (MTT) and general renal performance (GRP) together with glomerular filtration rate (GFR) were determined in 20 patients with T2DM before (T2DMbaseline) and 2 weeks after initiation of therapy with SGLT2i (T2DMSGLT2i). Additionally, dynamic FDG PET data of 24 healthy subjects were used as controls.ResultsMTT in T2DMbaseline was significantly higher than in healthy controls (5.7 min vs 4.3 min, p=0.012) and significantly decreased to 4.4 min in T2DMSGLT2i (p=0.004). GRP of T2DMSGLT2i was higher than of T2DMbaseline (5.2 vs 4.7, p=0.02) and higher but not significantly than of healthy individuals (5.2 vs 5.1, p=0.34). Expectedly, GFR of healthy participants was significantly higher than of T2DMbaseline and T2DMSGLT2i (122 vs 92 and 86 mL/min/1.73 m², respectively; p<0.001). The higher the GRP value in kidneys of T2DMSGLT2i, the lower was the glycated hemoglobin level 3 months after therapy initiation.ConclusionMTT and GRP values of patients with T2DM shifted significantly toward values of healthy control 2 weeks after therapy with SGLT2i begins. GRP in T2DMSGLT2i was associated with better long-term glycemic response 3 months after initiation of therapy.Trial registration numberNCT03557138.

Download Full-text

Basal insulin therapy in patients with type 2 diabetes mellitus: aspects of early initiation, advantages, constraints, and prospects

Problems of Endocrinology ◽

10.14341/probl201157353-59 ◽

2011 ◽

Vol 57 (3) ◽

pp. 53-59

Author(s):

O K Vikulova

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Insulin Therapy ◽

Intensive Therapy ◽

Cardiovascular Complications ◽

Optimal Regime ◽

Long Term Prognosis

Intensive control of glycemia starting from the onset of type 2 diabetes mellitus (DM2) is of primary importance for the long-term prognosis of the disease and the reduction of risk of cardiovascular complications. The strategy of early intensive therapy of DM2 thus far remains a matter of fierce dispute among diabetologists. The problem of choice of an optimal regime for the start of insulin therapy does not have an unambiguous solution either. Hypoglycemia is the main factor that traditionally hampers wide application of insulin therapy in patients with type 2 diabetes mellitus. The choice in favour of basal therapy with insulin analogs has the advantage of reaching the target parameters of carbohydrate metabolism at a significantly lower risk of hypoglycemia compared with other strategies of insulin therapy.

Download Full-text

Diabetes mellitus type 2 and acute myocardial infarction: prognostic options for interaction in patients of different age groups

Diabetes Mellitus ◽

10.14341/dm8828 ◽

2018 ◽

Vol 21 (2) ◽

pp. 105-112 ◽

Cited By ~ 1

Author(s):

Alla A. Garganeeva ◽

Elena A. Kuzheleva ◽

Ksenia N. Borel ◽

Dina S. Kondratyeva ◽

Sergey A. Afanasiev

Keyword(s):

Diabetes Mellitus ◽

Myocardial Infarction ◽

Type 2 Diabetes ◽

Acute Myocardial Infarction ◽

Type 2 Diabetes Mellitus ◽

Heart Disease ◽

Ischaemic Heart Disease ◽

Working Age

Background. Problems surrounding comorbidities of type 2 diabetes mellitus and coronary heart disease are some of the most important in medical science and practice, given their mutually negative impact on patients prognoses and quality of life. Aims. To study the impact of type 2 diabetes on the long-term prognoses of patients of different age categories, status-post acute myocardial infarction. (Data obtained from the Register of Acute Myocardial Infarction.) Materials and methods. The main data source was the Register of Acute Myocardial Infarction, maintained in Tomsk for more than 30 years. The study included 862 patients with acute myocardial infarction. The patients were monitored for 5 years. The primary endpoint was death from any cause during the observation period. Results. We separated the study cohort into 2 groups depending on patients ages: Group 1 (n = 358) included patients older than working age, Group 2 (n = 504) consisted of younger, employable patients. The combination of ischaemic heart disease and type 2 diabetes mellitus were diagnosed in 208 patients. The combination of ischaemic heart disease and type 2 diabetes was the cause of adverse prognosis among elderly patients and led to increased mortality rate during the 5-year post-infarction period (p = 0.0003). However, among younger, working patients who suffered myocardial infarction, the presence of type 2 diabetes did not have an independent negative effect on long-term disease prognosis. While in employable patients, a long history of diabetes mellitus significantly aggravated the course of the post-infarction period (p = 0.004). Conclusions. These data suggest an ambiguous prognostic effect of type 2 diabetes mellitus among working age and elderly patients status post myocardial infarction, in agreement with experimental studies conducted on laboratory animals. Further comprehensive analyses of the clinical and experimental data are needed to optimise therapies for patients who suffer from type 2 diabetes and comorbid ischaemic heart disease.

Download Full-text

The Impact of Renal Dysfunction on Outcomes of In-Hospital and Remote Periods in Patients With ST-Elevation Myocardial Infarction Combined With Type 2 Diabetes Mellitus

Kardiologiia ◽

10.18565/cardio.2015.11.24-30 ◽

2015 ◽

Vol 11_2015 ◽

pp. 24-30 ◽

Cited By ~ 1

Author(s):

V.N. Karetnikova Karetnikova ◽

M.V. Evseeva Evseeva ◽

M.V. Zykov Zykov ◽

I.S. Bykova Bykova ◽

V.V. Kalaeva Kalaeva ◽

...

Keyword(s):

Diabetes Mellitus ◽

Myocardial Infarction ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Renal Dysfunction ◽

St Elevation Myocardial Infarction ◽

St Elevation ◽

The Impact

Download Full-text

Effects of n-3 fatty acids on long-term outcomes of high risk patients with type 2 diabetes mellitus or IGF/IGT with a recent myocardial infarction

European Heart Journal ◽

10.1093/eurheartj/eht308.1966 ◽

2013 ◽

Vol 34 (suppl 1) ◽

pp. 1966-1966 ◽

Cited By ~ 5

Author(s):

A. P. Maggioni ◽

G. Fabbri ◽

J. Bosch ◽

L. Dyal ◽

L. E. Ryden ◽

...

Keyword(s):

Diabetes Mellitus ◽

Myocardial Infarction ◽

Type 2 Diabetes ◽

Fatty Acids ◽

Type 2 Diabetes Mellitus ◽

High Risk ◽

Long Term Outcomes ◽

Risk Patients

Download Full-text

The importance of three-stage cardiac rehabilitation in patients with acute coronary syndrome and type 2 diabetes mellitus

Medical Council ◽

10.21518/2079-701x-2020-11-12-18 ◽

2020 ◽

pp. 12-18

Author(s):

E. A. Nikitina ◽

E. N. Chicherina ◽

O. S. Elsukova ◽

I. S. Metelev

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Acute Coronary Syndrome ◽

Myocardial Revascularization ◽

Diabetic Patients ◽

Coronary Syndrome ◽

Long Term Prognosis

Introduction. Acute coronary syndrome (ACS) patients with type 2 diabetes mellitus (T2DM) have worse prognosis than those without diabetes. Risk of adverse outcome in this cohort remains high despite the introduction of new methods of invasive treatment of ACS. The use of all-inclusive cardiac rehabilitation (CR) programs allows improving prognosis in patients with ACS and T2DM. Aim. The aim of the study was to evaluate impact of two- or three-stage CR on long-term prognosis in patients with ACS and T2DM. Methods. The study included 251 ACS patients hospitalized in the department of cardiology, of which 120 patients with T2DM. Management of ACS was carried out in accordance with the clinical recommendations of the European Society of Cardiology (2015, 2017). All patients underwent standard laboratory and instrumental examination. We analyzed prognostic parameters (myocardial revascularization, myocardial infarction and mortality) during 12 months of follow-up in diabetic and non-diabetic patients with ACS who underwent two or a three-stage CR. Additionally, the achievement of the combined endpoint, which include at least one of the ACE, was analyzed. Results. Long-term prognosis in ACS patients who underwent three-stage CR in diabetic and non-diabetic groups did not differ significantly. However, the frequency of repeated myocardial revascularization was higher in patients with T2DM in comparison with non-diabetic patients inside the two-stage CR subgroup. Conclusion. Three-stage CR should be recommended in diabetic patients with ACS to improve long-term prognosis.

Download Full-text